| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Kilitch Drugs (India) Limited (NSE: KILITCH)
KILITCH Technical Analysis
2
| As on 16th Apr 2024 KILITCH SHARE Price closed @ 349.30 and we RECOMMEND Buy for LONG-TERM with Stoploss of 234.06 & Strong Sell for SHORT-TERM with Stoploss of 391.48 we also expect STOCK to react on Following IMPORTANT LEVELS. |
KILITCHSHARE Price
| Open | 343.25 | Change | Price | % |
| High | 365.05 | 1 Day | -0.50 | -0.14 |
| Low | 342.10 | 1 Week | -20.85 | -5.63 |
| Close | 349.30 | 1 Month | -15.65 | -4.29 |
| Volume | 5910 | 1 Year | 181.45 | 108.10 |
| 52 Week High 262.00 | 52 Week Low 79.85 | ||||
NSE INDIA Most Active Stocks
| IDEA | 12.95 | -1.52% |
| YESBANK | 23.95 | 0.00% |
| ONGC | 283.15 | 1.18% |
| EXIDEIND | 459.80 | 12.41% |
| NHPC | 91.20 | 2.53% |
| IDFCFIRSTB | 82.70 | -0.06% |
| PNB | 128.55 | -3.24% |
| ZOMATO | 186.45 | -0.98% |
| DHANI | 48.00 | 15.38% |
| TATASTEEL | 160.05 | -0.50% |
NSE INDIA Top Gainers Stocks
| DSSL | 1131.95 | 20.00% |
| HINDMOTORS | 21.95 | 19.95% |
| WABAG | 923.90 | 15.50% |
| DHANI | 48.00 | 15.38% |
| BHAGERIA | 185.45 | 15.15% |
| AKASH | 40.95 | 13.43% |
| MARKSANS | 176.70 | 13.38% |
| EXIDEIND | 459.80 | 12.41% |
| JAGSNPHARM | 321.45 | 11.89% |
| SOTL | 542.55 | 10.85% |
NSE INDIA Top Losers Stocks
| KILITCH Daily Charts |
KILITCH Intraday Charts |
Whats New @ Bazaartrend |
KILITCH Free Analysis |
|
|
KILITCH Important Levels Intraday
| RESISTANCE | 393.52 |
| RESISTANCE | 379.34 |
| RESISTANCE | 370.57 |
| RESISTANCE | 361.81 |
| SUPPORT | 336.79 |
| SUPPORT | 328.03 |
| SUPPORT | 319.26 |
| SUPPORT | 305.08 |
KILITCH Target April 2024
| 4th UP Target | 580.67 |
| 3rd UP Target | 517.76 |
| 2nd UP Target | 478.87 |
| 1st UP Target | 439.98 |
| 1st DOWN Target | 329.02 |
| 2nd DOWN Target | 290.13 |
| 3rd DOWN Target | 251.24 |
| 4th DOWN Target | 188.33 |
KILITCH Weekly Target
| 4th UP Target | 421.52 |
| 3rd UP Target | 400.51 |
| 2nd UP Target | 387.52 |
| 1st UP Target | 374.53 |
| 1st DOWN Target | 337.47 |
| 2nd DOWN Target | 324.48 |
| 3rd DOWN Target | 311.49 |
| 4th DOWN Target | 290.48 |
KILITCH Target2024
| 4th UP Target | 424 |
| 3rd UP Target | 357.97 |
| 2nd UP Target | 317.15 |
| 1st UP Target | 276.33 |
| 1st DOWN Target | 159.87 |
| 2nd DOWN Target | 119.05 |
| 3rd DOWN Target | 78.23 |
| 4th DOWN Target | 12.2 |
Kilitch Drugs (India) Limited ( NSE INDIA Symbol : KILITCH )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
KILITCH Synopsis Technicals View
| 50 Day EMA |
Close is Above EMA 50 (Short Term) |
Bullish | |
| 100 Day EMA | Close is Above EMA 100 (Mid Term) | Bullish | |
| 200 Day EMA | Close is Above EMA 200 (Long Term) | Bullish | |
| MACD (12 26 9) | MACD Line is Less Then SIGNAL Line | Bearish | |
| RSI (14) | RSI is 39.69 | Sideways | |
| MFI (14) | MFI is 53.36 | Sideways | |
| CCI (20) | CCI is -46.39 | Sideways | |
| WILLIAM %R (14) | William %R is -44.39 | Sideways | |
| ADX (14) | ADX is Above 20 & +DI is Below -DI | Down Trend | |
| PSAR | Stoploss For Long Buy | 61.84 | |
| 10 Day Avg Volume | Traded -27.20 % Less then 10 Day Average Volume | ||
KILITCH Other Details
| Segment | EQ | |
| Market Capital | 2549692160.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > | |
KILITCH Address
 |
||
KILITCH Latest News
KILITCH Business Profile
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India. Address: 37/39, Ujagar Industrial Estate, Mumbai, India, 400088
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service